On December 16, Biohaven Pharmaceuticals’ Taldefgrobep Alfa was granted orphan designation as a treatment of spinal muscular atrophy, according to a post to the FDA’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BHVN:
- Cowen says full sale of BioCryst ‘potentially now even more likely’
- Biohaven initiated with a Buy at BTIG
- George Soros Pulls the Trigger on These 2 “Strong Buy” Stocks
- Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
- Significant Insider Trading at Biohaven (NYSE:BHVN) Following its $25M Public Offering